{'_data': [['Unknown',
            [['GI',
              u'disorders General disorders thirst and administration site conditions With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change. Cumulatively, 502 paediatric patients 2 to 5 years of age were treated with montelukast for at least 3 months, 338 for 6 months or longer, and 534 patients for 12 months or longer. With prolonged treatment, the safety profile did not change in these patients either.'],
             ['GI',
              u'diarrhoea, dry mouth, dyspepsia, nausea, vomiting Hepatobiliary disorders elevated levels of serum transaminases (ALT, AST), hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury) Skin and subcutaneous tissue disorders angioedema, bruising, urticaria, pruritus, rash, erythema nodosum Musculoskeletal and connective tissue disorders arthralgia, myalgia including muscle cramps General disorders and administration site conditions asthenia/fatigue, malaise, oedema, pyrexia Very rare cases of Churg-Strauss Syndrome (CSS) have been reported during montelukast treatment in asthmatic patients (see section 4.4.)']]]],
 '_pages': [6, 8],
 u'_rank': 2,
 u'_type': u'LSFU'}